Evidence map›Paper›PMID 41581944›Full record

ReviewGastroenterology clinics of North America2026

Diagnostic and Prognostic Biomarkers for Barrett's Esophagus.

Fangfang Wang, Allon Kahn, John B Kisiel, Prasad G Iyer

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology clinics of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fangfang WangBarrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, USA.
Allon KahnBarrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, USA.
John B KisielDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, 200 1st Street Southwest, Rochester, MN, USA.
Prasad G IyerBarrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, USA. Electronic address: Iyer.Prasad@mayo.edu.

Funding

Minimally Invasive Molecular Approaches for the Detection of Barrett’s Esophagus and Esophageal AdenocarcinomaR01CA241164 · NCI · MAYO CLINIC ROCHESTER · PI Jagpreet Chhatwal, Prasad G. Iyer · 2019 to 2026
$3.9M
NCI NIH HHS R01 CA241164
6 · The paper itself

Abstract

The increasing burden of esophageal adenocarcinoma (EAC) has driven efforts to improve early detection and risk stratification. Barrett's esophagus (BE), the only known precursor to EAC, presents an opportunity for screening and surveillance. This article highlights major advances in molecular biomarkers for BE, such as the Cytosponge-TFF3 test, methylated DNA markers, p53, aneuploidy, and other emerging biomarkers. Their integration into clinical practice may transform esophageal cancer detection and prevention by enabling precision screening and surveillance and by broadening access to care.

Indexed as

AdenocarcinomaBarrett EsophagusBiomarkers, TumorEsophageal NeoplasmsPrecancerous ConditionsAneuploidyDNA MethylationEarly Detection of CancerHumansPrognosisTrefoil Factor-3Tumor Suppressor Protein p53Biomarkers, TumorTFF3 protein, humanTrefoil Factor-3Tumor Suppressor Protein p53Barrett esophagusBiomarkersEarly detection of cancerEsophageal neoplasms/diagnosisPrognosis

Identifiers

PMID41581944
PMCPMC13285082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.